Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
27.47
-0.31 (-1.12%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Denali Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Denali Therapeutics stock have an average target of 38.22, with a low estimate of 22 and a high estimate of 90. The average target predicts an increase of 39.13% from the current stock price of 27.47.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for DNLI stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 9 | 9 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $29 → $28 | Buy | Maintains | $29 → $28 | +1.93% | Oct 11, 2024 |
| Raymond James | Raymond James | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Oct 10, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $35 | Buy | Reiterates | $35 | +27.41% | Sep 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +227.63% | Sep 4, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $25 → $29 | Strong Buy | Maintains | $25 → $29 | +5.57% | Sep 4, 2024 |
Financial Forecast
Revenue This Year
21.42M
from 330.53M
Decreased by -93.52%
Revenue Next Year
59.25M
from 21.42M
Increased by 176.62%
EPS This Year
-2.58
from -1.06
EPS Next Year
-2.73
from -2.58
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 52.5M | 164.3M | 513.6M | ||
| Avg | 21.4M | 59.3M | 164.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -84.1% | 667.2% | 766.9% | ||
| Avg | -93.5% | 176.6% | 178.1% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.27 | -2.35 | -0.61 | ||
| Avg | -2.58 | -2.73 | -2.10 | ||
| Low | -2.70 | -3.17 | -2.96 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.